Once-weekly subcutaneous tirzepatide may not raise risk for depression compared with placebo, according to a post hoc analysis of the SURMOUNT trials.
As Healio previously reported, in January the FDA requested that risk for suicidal ideation and behaviors be removed from labels for liraglutide (Saxenda, Novo Nordisk), injectable semaglutide 2.4 mg (Wegovy, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly).
In data published in Obesity, researchers found adults receiving tirzepatide in three SURMOUNT trials did not experience worsening of depression throughout the studies.
“The low occurrence

Specialists in multiple sclerosis will gather in San Diego for ACTRIMS Forum 2026, Feb. 5-7, where the theme will be “MS at a Crossroads.”
“There’s been a huge amount of progress in the field of MS,” Jiwon Oh, MD, vice chair of the ACTRIMS program committee, told Healio. “But there’s many things that are emerging that make us rethink the way we’re looking at many things that we used to think were ground truth.”
The way that clinicians consider disease pathobiology is one of those issues, said Oh, who also is the medical director of the Barlo

Individuals with knee osteoarthritis who had low activity levels in the morning and evening demonstrated a two-fold higher risk for earlier mortality than other patients, according to data published in Arthritis Care & Research.
“We were interested in whether there were different patterns of physical activity within the day, and if such patterns were related to health outcomes in adults with knee OA, specifically mortality in this particular study,” Daniel K. White, PT, ScD, MSc, associate professor at the University of Delaware, told Healio. “The thought is that our

Women on peritoneal dialysis had significantly lower risks than men for mortality, transfers to hemodialysis and other kidney outcomes, according to study data published in the Clinical Journal of the American Society of Nephrology.
PD is currently used by 11% of patients with kidney failure globally, but the sex-specific outcomes tied to PD are not well understood, according to Rehab B. Albakr, MD, a nephrologist at King Saud University Medical City in Saudi Arabia, and colleagues. Understanding sex disparities and outcomes in PD could help to increase its utilization, they wrote.
“There is a

The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic pulmonary fibrosis into its Biomarker Qualification Program, according to a press release.
The Prognostic Lung Fibrosis Consortium (PROLIFIC) Risk Score is based on a panel of five serum proteins involved in lung cell injury, scarring and inflammation and can predict a patient’s likelihood for death, lung transplantation or lung function reduction, Peter Schafer, PhD, chair of PROLIFIC, told Healio.
The hope for the risk score is that it will serve as a stratification factor or

Clinical and health care resource use burden were greater among patients with diagnosed hypereosinophilic syndrome or predicted hypereosinophilic syndrome via machine learning vs. those without the condition, according to study data.
These results were published in The Journal of Allergy and Clinical Immunology: In Practice.
“These are patients that might present to a variety of different providers,” Princess U. Ogbogu, MD, division chief of pediatric allergy, immunology and rheumatology at University Hospitals and professor at Case Western Reserve University School of Medicine, told Healio.